MX2019013670A - Formulaciones de anticuerpos y proteinas. - Google Patents
Formulaciones de anticuerpos y proteinas.Info
- Publication number
- MX2019013670A MX2019013670A MX2019013670A MX2019013670A MX2019013670A MX 2019013670 A MX2019013670 A MX 2019013670A MX 2019013670 A MX2019013670 A MX 2019013670A MX 2019013670 A MX2019013670 A MX 2019013670A MX 2019013670 A MX2019013670 A MX 2019013670A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- protein formulations
- formulations
- protein
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Se proporcionan formulaciones sin sal de anticuerpos y otras proteínas que son sustancialmente isosmóticas y de baja viscosidad. También se proporcionan procedimientos para el tratamiento de enfermedades usando las formulaciones divulgadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/601,598 US8613919B1 (en) | 2012-08-31 | 2012-08-31 | High concentration antibody and protein formulations |
US13/843,780 US9592297B2 (en) | 2012-08-31 | 2013-03-15 | Antibody and protein formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019013670A true MX2019013670A (es) | 2020-01-15 |
Family
ID=49162239
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015002411A MX369653B (es) | 2012-08-31 | 2013-08-28 | Formulaciones de anticuerpos y proteinas. |
MX2019013670A MX2019013670A (es) | 2012-08-31 | 2015-02-24 | Formulaciones de anticuerpos y proteinas. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015002411A MX369653B (es) | 2012-08-31 | 2013-08-28 | Formulaciones de anticuerpos y proteinas. |
Country Status (26)
Country | Link |
---|---|
US (7) | US9592297B2 (es) |
EP (3) | EP2890718A1 (es) |
JP (3) | JP6462567B2 (es) |
CN (2) | CN104684933B (es) |
AR (2) | AR092388A1 (es) |
AU (3) | AU2013308902B2 (es) |
BR (1) | BR112015003838A2 (es) |
CA (2) | CA2883095C (es) |
CY (1) | CY1121989T1 (es) |
DK (1) | DK3117837T3 (es) |
ES (1) | ES2741575T3 (es) |
HK (1) | HK1210794A1 (es) |
HR (1) | HRP20191299T1 (es) |
HU (1) | HUE045652T2 (es) |
IL (6) | IL286784B (es) |
LT (1) | LT3117837T (es) |
MX (2) | MX369653B (es) |
PL (1) | PL3117837T3 (es) |
PT (1) | PT3117837T (es) |
RS (1) | RS59221B1 (es) |
RU (2) | RU2678097C2 (es) |
SG (2) | SG10201708215YA (es) |
SI (1) | SI3117837T1 (es) |
TW (4) | TW201927338A (es) |
UY (1) | UY34995A (es) |
WO (1) | WO2014036071A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2542257T (lt) | 2010-03-01 | 2017-11-27 | Bayer Healthcare Llc | Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi) |
EP2694544B1 (en) * | 2011-04-01 | 2019-01-23 | Bayer HealthCare LLC | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
AT512589B1 (de) * | 2012-03-12 | 2014-06-15 | Zizala Lichtsysteme Gmbh | Lichtleitelement für einen Laser-Fahrzeugscheinwerfer sowie Fahrzeugscheinwerfer |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
RU2675824C2 (ru) | 2013-09-11 | 2018-12-25 | Игл Байолоджикс, Инк. | Жидкие белковые составы, содержащие ионные жидкости |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
TWI707870B (zh) | 2014-10-01 | 2020-10-21 | 英商梅迪繆思有限公司 | 針對替格瑞洛的抗體及使用方法 |
WO2016054259A1 (en) | 2014-10-01 | 2016-04-07 | Arsia Therapeutics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
NZ739871A (en) | 2015-08-19 | 2022-05-27 | Pfizer | Tissue factor pathway inhibitor antibodies and uses thereof |
DK3337502T3 (da) | 2015-08-19 | 2020-09-14 | Astrazeneca Ab | Stabil anti-ifnar1-formulering |
CN108025072A (zh) * | 2015-09-22 | 2018-05-11 | 辉瑞公司 | 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂 |
JP2019511531A (ja) * | 2016-04-13 | 2019-04-25 | メディミューン,エルエルシー | 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用 |
EA201892653A1 (ru) | 2016-06-30 | 2019-05-31 | Селлтрион Инк. | Стабильный жидкий фармацевтический состав |
JP2019527729A (ja) * | 2016-07-13 | 2019-10-03 | リフォーム バイオロジクス、エルエルシー | 治療用タンパク質製剤のための安定化賦形剤 |
KR20190053908A (ko) | 2016-09-16 | 2019-05-20 | 로이코케어 아게 | 가공 동안 바이오 의약품의 안정화를 위한 신규한 방법 |
EA201900326A1 (ru) * | 2016-12-23 | 2019-11-29 | Усовершенствованные способы повышения продуктивности антител в культурах клеток млекопитающих и сведения к минимуму агрегации в процессах выделения и очистки, получения композиций и стабильные композиции антител, полученные этими способами | |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
MX2019013072A (es) | 2017-05-02 | 2019-12-16 | Merck Sharp & Dohme | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. |
MX2020011848A (es) | 2018-05-10 | 2021-03-29 | Regeneron Pharma | Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración. |
AU2019297498A1 (en) * | 2018-07-05 | 2021-01-21 | Bayer Aktiengesellschaft | Method for the production of freeze-dried pellets comprising an anti-coagulation factor xia (FXIa) antibody |
KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
US20210324052A1 (en) * | 2018-10-18 | 2021-10-21 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
CN111346225A (zh) * | 2018-12-21 | 2020-06-30 | 上海张江生物技术有限公司 | 含有蛋白质的药物制剂 |
CA3160806A1 (en) * | 2019-11-13 | 2021-05-20 | Pfizer Inc. | Stable aqueous formulation containing anti-tfpi antibody _______ |
WO2024026388A1 (en) * | 2022-07-27 | 2024-02-01 | Viela Bio, Inc. | Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1064396A (en) | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
US4075193A (en) | 1976-11-26 | 1978-02-21 | Parke, Davis & Company | Process for producing intravenous immune globulin |
US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
US4499073A (en) | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
ES2044941T5 (es) | 1987-08-21 | 1999-02-16 | Mallinckrodt Group Inc | Estabilizador de hormonas promotoras del crecimiento. |
US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
US4912861A (en) * | 1988-04-11 | 1990-04-03 | Huang Ing Chung | Removable pressure-adjustable shock-absorbing cushion device with an inflation pump for sports goods |
US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
EP0417193B1 (en) | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
CA2049342A1 (en) | 1989-03-27 | 1990-09-28 | Sally Bolmer | Formulations for stabilizing of igm antibodies |
US5217954A (en) | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
JP2966592B2 (ja) | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
US5849700A (en) | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
JP3698721B2 (ja) | 1993-02-23 | 2005-09-21 | ジェネンテク・インコーポレイテッド | 有機溶媒を用いて処理したポリペプチドの賦形剤安定化 |
DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
CN1151842C (zh) | 1995-07-27 | 2004-06-02 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白制剂 |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6686191B1 (en) | 1995-09-22 | 2004-02-03 | Bayer Healthcare Llc | Preparation of virally inactivated intravenously injectable immune serum globulin |
DE59710863D1 (de) | 1996-01-25 | 2003-11-20 | Schering Ag | Verbesserte kontrastmittenlösungen für die intravasale anwendung |
US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
KR100236393B1 (ko) | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
WO1999011091A1 (de) | 1997-08-21 | 1999-03-04 | Siemens Aktiengesellschaft | Verfahren zum übertragen von nutzdaten, die unterschiedlichen anwendungen zuordenbar sind |
GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
JP2000247903A (ja) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
NZ535205A (en) | 1999-10-04 | 2006-01-27 | Chiron Corp | Stabilized liquid interleukin-2 ( IL-2 ) containing pharmaceutical compositions |
WO2001064241A1 (fr) | 2000-02-29 | 2001-09-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a long terme |
WO2001076621A2 (en) | 2000-04-07 | 2001-10-18 | Kline Ellis L | Methods and compositions for treating neoplasms |
US20040038878A1 (en) | 2000-08-04 | 2004-02-26 | Masahiko Tanikawa | Injectable protein formulations |
EP2311492B1 (en) | 2000-08-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing stabilized preparations |
EP1329224A4 (en) | 2000-09-01 | 2004-04-14 | Chugai Pharmaceutical Co Ltd | PREPARATIONS OF STABILIZED SOLUTIONS OVER A LONG PERIOD OF TIME |
PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
EP1409018B1 (en) | 2001-07-25 | 2010-01-06 | Facet Biotech Corporation | Stable lyophilized pharmaceutical formulation the igg antibody daclizumab |
AU2002335815A1 (en) | 2001-10-16 | 2003-04-28 | Rxkinetix, Inc. | High-concentration protein formulations and method of manufacture |
US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
US20030138416A1 (en) | 2001-12-03 | 2003-07-24 | Jesper Lau | Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
AU2002351353A1 (en) | 2001-12-19 | 2003-09-02 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
US20050118163A1 (en) | 2002-02-14 | 2005-06-02 | Hidefumi Mizushima | Antibody-containing solution pharmaceuticals |
WO2003072060A2 (en) | 2002-02-27 | 2003-09-04 | Immunex Corporation | Polypeptide formulation |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
AU2003251592A1 (en) | 2002-06-21 | 2004-01-06 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
WO2004007520A2 (en) | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
KR101080716B1 (ko) | 2002-10-08 | 2011-11-07 | 리나트 뉴로사이언스 코퍼레이션 | 신경성장인자 길항제를 투여함에 의한 수술-후 통증의치료방법 및 그를 함유하는 조성물 |
WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
US7449616B2 (en) | 2002-12-24 | 2008-11-11 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
GEP20146050B (en) | 2003-07-15 | 2014-03-10 | Medarex Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
AU2004277466C1 (en) | 2003-10-01 | 2022-06-23 | Kyowa Kirin Co., Ltd. | Method of stabilizing antibody and stabilized solution-type antibody preparation |
EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
US20070184050A1 (en) | 2003-12-25 | 2007-08-09 | Kirin Beer Kabushiki Kaisha | Stable water-based medicinal preparation containing antibody |
EP1755677A4 (en) | 2004-06-14 | 2009-11-25 | Medimmune Vaccines Inc | HIGH-PRESSURE SPRAY DRYING OF BIOACTIVE MATERIALS |
US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1841456A2 (en) | 2005-01-28 | 2007-10-10 | Wyeth | Stabilized liquid polypeptide formulations |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
JP5670004B2 (ja) | 2005-03-08 | 2015-02-18 | ファイザー・プロダクツ・インク | 抗ctla−4抗体組成物 |
TW200714290A (en) | 2005-03-08 | 2007-04-16 | Pharmacia & Upjohn Co Llc | Anti-M-CSF antibody compositions having reduced levels of endotoxin |
AU2005330672B2 (en) | 2005-04-18 | 2011-07-28 | Yeda Research And Development Company Limited | Stabilized anti-hepatitis B (HBV) antibody formulations |
KR20080025174A (ko) * | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
JP5033798B2 (ja) | 2005-07-02 | 2012-09-26 | アレコー・リミテッド | タンパク質を含む安定水系 |
EP1917030A4 (en) | 2005-08-03 | 2011-03-09 | Immunogen Inc | IMMUNKONJUGATFORMULIERUNGEN |
US7790679B2 (en) | 2005-08-05 | 2010-09-07 | Amgen Inc. | Pharmaceutical formulations |
AU2006315026B2 (en) | 2005-11-21 | 2012-11-22 | Sanofi Pasteur Limited | Stabilizing formulations for recombinant viruses |
EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
EP1988922A4 (en) | 2006-02-03 | 2010-06-02 | Medimmune Llc | PROTEIN FORMULATIONS |
DE102006005094A1 (de) | 2006-02-04 | 2007-08-09 | Degussa Gmbh | Titandioxid und Polycarboxylatether enthaltende Dispersion |
CN101466404A (zh) | 2006-06-14 | 2009-06-24 | 埃姆克隆系统股份有限公司 | 抗-egfr抗体的冻干制剂 |
ES2656359T3 (es) | 2006-06-30 | 2018-02-26 | Novo Nordisk A/S | Anticuerpos anti-NKG2A y usos de los mismos |
CA2665423A1 (en) | 2006-10-12 | 2008-04-17 | Wyeth | Methods and compositions with reduced opalescence |
PE20081477A1 (es) | 2006-12-11 | 2008-10-18 | Hoffmann La Roche | Formulacion liofilizada mab abeta |
CA2682170A1 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
AU2008266051B2 (en) | 2007-06-14 | 2014-07-31 | Biogen Ma Inc. | Antibody formulations |
CA2692165A1 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
JP5490714B2 (ja) | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
EP2222706B2 (en) | 2007-12-14 | 2016-08-10 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
UA101487C2 (en) * | 2007-12-21 | 2013-04-10 | Ф. Хоффманн-Ля Рош Аг | Humanized b-ly1 antibody formulation |
US20110014203A1 (en) | 2007-12-28 | 2011-01-20 | Fredrik Nilsson | Formulation |
WO2009103113A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | HUMANIZED ANTI-C5aR ANTIBODIES |
WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
KR20110039218A (ko) | 2008-06-30 | 2011-04-15 | 노보 노르디스크 에이/에스 | 항-인간 인터루킨-20 항체 |
UA112050C2 (uk) | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
AU2009294214B2 (en) | 2008-09-19 | 2014-04-24 | Pfizer Inc. | Stable liquid antibody formulation |
JP2012510468A (ja) * | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
RU2562114C2 (ru) | 2008-12-22 | 2015-09-10 | Ново Нордиск А/С | Антитела против ингибитора метаболического пути тканевого фактора |
AR076640A1 (es) | 2009-03-06 | 2011-06-29 | Genentech Inc | Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura |
AU2010263058A1 (en) | 2009-06-18 | 2012-01-12 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
EP3438126B1 (en) | 2009-09-03 | 2020-08-19 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
LT2542257T (lt) | 2010-03-01 | 2017-11-27 | Bayer Healthcare Llc | Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi) |
JPWO2011108452A1 (ja) * | 2010-03-02 | 2013-06-27 | Jnc株式会社 | 還元反応器 |
JP5730983B2 (ja) * | 2010-03-19 | 2015-06-10 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Tfpi阻害剤および使用方法 |
EP2575761A1 (en) * | 2010-05-28 | 2013-04-10 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
EP3733711A1 (en) * | 2010-10-06 | 2020-11-04 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
EP2694544B1 (en) | 2011-04-01 | 2019-01-23 | Bayer HealthCare LLC | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
-
2013
- 2013-03-15 US US13/843,780 patent/US9592297B2/en active Active
- 2013-08-28 EP EP13760179.5A patent/EP2890718A1/en not_active Withdrawn
- 2013-08-28 RU RU2015111341A patent/RU2678097C2/ru not_active IP Right Cessation
- 2013-08-28 LT LTEP16180643.5T patent/LT3117837T/lt unknown
- 2013-08-28 MX MX2015002411A patent/MX369653B/es active IP Right Grant
- 2013-08-28 ES ES16180643T patent/ES2741575T3/es active Active
- 2013-08-28 HU HUE16180643A patent/HUE045652T2/hu unknown
- 2013-08-28 JP JP2015529977A patent/JP6462567B2/ja active Active
- 2013-08-28 CN CN201380051319.0A patent/CN104684933B/zh active Active
- 2013-08-28 AU AU2013308902A patent/AU2013308902B2/en not_active Ceased
- 2013-08-28 BR BR112015003838A patent/BR112015003838A2/pt not_active Application Discontinuation
- 2013-08-28 EP EP16180643.5A patent/EP3117837B1/en active Active
- 2013-08-28 CA CA2883095A patent/CA2883095C/en active Active
- 2013-08-28 RU RU2019100887A patent/RU2019100887A/ru not_active Application Discontinuation
- 2013-08-28 DK DK16180643.5T patent/DK3117837T3/da active
- 2013-08-28 SG SG10201708215YA patent/SG10201708215YA/en unknown
- 2013-08-28 SG SG11201501116RA patent/SG11201501116RA/en unknown
- 2013-08-28 WO PCT/US2013/056970 patent/WO2014036071A1/en active Application Filing
- 2013-08-28 PL PL16180643T patent/PL3117837T3/pl unknown
- 2013-08-28 PT PT16180643T patent/PT3117837T/pt unknown
- 2013-08-28 US US14/421,607 patent/US20150209431A1/en not_active Abandoned
- 2013-08-28 RS RSP20190976 patent/RS59221B1/sr unknown
- 2013-08-28 IL IL286784A patent/IL286784B/en unknown
- 2013-08-28 EP EP19175217.9A patent/EP3590536A1/en not_active Ceased
- 2013-08-28 CA CA3129277A patent/CA3129277A1/en active Pending
- 2013-08-28 CN CN202111330122.3A patent/CN114392353A/zh active Pending
- 2013-08-28 SI SI201331538T patent/SI3117837T1/sl unknown
- 2013-08-28 IL IL294567A patent/IL294567A/en unknown
- 2013-08-29 AR ARP130103085A patent/AR092388A1/es unknown
- 2013-08-29 UY UY0001034995A patent/UY34995A/es not_active Application Discontinuation
- 2013-08-30 TW TW108113538A patent/TW201927338A/zh unknown
- 2013-08-30 TW TW102131180A patent/TWI609697B/zh not_active IP Right Cessation
- 2013-08-30 TW TW106131685A patent/TW201825116A/zh unknown
- 2013-08-30 TW TW102131326A patent/TW201414496A/zh unknown
- 2013-08-30 AR ARP130103099A patent/AR092400A1/es unknown
- 2013-12-16 US US14/107,658 patent/US20140105892A1/en not_active Abandoned
-
2014
- 2014-08-12 US US14/457,408 patent/US9849181B2/en active Active
-
2015
- 2015-02-11 IL IL237188A patent/IL237188A0/en unknown
- 2015-02-24 MX MX2019013670A patent/MX2019013670A/es unknown
- 2015-11-27 HK HK15111675.2A patent/HK1210794A1/xx unknown
-
2017
- 2017-08-16 US US15/679,053 patent/US20180055940A1/en not_active Abandoned
- 2017-10-18 US US15/787,610 patent/US20180028669A1/en not_active Abandoned
-
2018
- 2018-05-11 AU AU2018203320A patent/AU2018203320B2/en not_active Expired - Fee Related
- 2018-12-17 JP JP2018235273A patent/JP2019048886A/ja active Pending
-
2019
- 2019-04-07 IL IL265865A patent/IL265865A/en unknown
- 2019-04-07 IL IL265864A patent/IL265864B/en active IP Right Grant
- 2019-07-18 HR HRP20191299TT patent/HRP20191299T1/hr unknown
- 2019-08-16 CY CY20191100881T patent/CY1121989T1/el unknown
-
2020
- 2020-01-08 AU AU2020200134A patent/AU2020200134A1/en not_active Abandoned
- 2020-11-11 US US17/095,102 patent/US20230190637A9/en not_active Abandoned
- 2020-12-06 IL IL279237A patent/IL279237A/en unknown
-
2021
- 2021-01-13 JP JP2021003390A patent/JP2021059602A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019013670A (es) | Formulaciones de anticuerpos y proteinas. | |
MY191169A (en) | Anti-fcrh5 antibodies | |
PH12016501644B1 (en) | Binding proteins and methods of use thereof | |
PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
PH12015501954A1 (en) | Anti-b7-h4 antibodies and immunoconjugates | |
PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
PH12015500525A1 (en) | Formulations of enzalutamide | |
MX342240B (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
EP3604535A3 (en) | Methods and compositions for weed control | |
PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
MX354303B (es) | Anticuerpos de anti-biotina y metodos de uso. | |
MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
MX357675B (es) | Anticuerpos anti-jagged y métodos de uso. | |
MX2014014381A (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина | |
MX2015010789A (es) | Anticuerpos anti-pcsm. |